Clinical Trials Directory

Trials / Completed

CompletedNCT01168310

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination With Formoterol Fumarate in Subjects With COPD

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
468 (actual)
Sponsor
Dey · Industry
Sex
All
Age
40 Days
Healthy volunteers
Not accepted

Summary

This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

Conditions

Interventions

TypeNameDescription
DRUGFluticasone Propionate/Formoterol FumarateInhalation Suspension
DRUGFluticasone Propionate/Formoterol FumarateInhalation Suspension
DRUGFluticasone Propionate/Formoterol FumarateInhalation Suspension
DRUGFluticasone Propionate/Formoterol FumarateInhalation Suspension
DRUGFluticasone Propionate/Formoterol FumarateInhalation Suspension
DRUGFormoterol FumarateInhalation Solution
DRUGPlaceboInhalation Solution

Timeline

Start date
2010-08-01
Primary completion
2010-08-01
Completion
2011-10-01
First posted
2010-07-23
Last updated
2013-05-27

Locations

23 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01168310. Inclusion in this directory is not an endorsement.